Esomeprazole Market Share, Size, Trends, Industry Analysis Report, By Product (Capsules, Tablets, Injections, Others); By Application; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032
- Published Date:Feb-2024
- Pages: 116
- Format: PDF
- Report ID: PM4436
- Base Year: 2023
- Historical Data: 2019 – 2022
Report Outlook
Esomeprazole Market size was valued at USD 1,810.61 million in 2023. The market is anticipated to grow from USD 1,904.40 million in 2024 to USD 2,872.07 million by 2032, exhibiting the CAGR of 5.3% during the forecast period.
Market Overview
The increasing aging population and altering human lifestyle are major factors influencing the demand for Esomeprazole in the global market. Most of the working people are following hectic schedules, with the limited or no time for preparing meals and having balanced diet, leading to health complications related to the digestive system and acidity disorders. This is creating the critical need for the medicines that have the potential to reduce acid levels in their stomach by the people. The increasing number of research studies exploring esomeprazole health effects are expected to provide new growth opportunities in the coming years.
- For instance, in December 2023, a study published in BMC Gastroenterology focused on evaluating the efficiency and safety of dual delayed-release esomeprazole and delayed-release esomeprazole in treating erosive esophagitis. Results suggested that both are similarly effective in treating the disease.
To Understand More About this Research: Request a Free Sample Report
Moreover, the increasing incidence of acid reflux problems among adults are anticipated to drive demand for effective healthcare medication, including esomeprazole, driven by its tremendous potential in controlling acid burning. According to the Fortune Clinic, Mumbai, in 2023, approximately 20% of the patients in their outpatient department are suffering from acid reflux cases on a weekly basis. There will be a significant demand for esomeprazole in the future, as this trend continues further.
However, esomeprazole production requires a huge amount of cost due to its complex manufacturing process, leading to the lower supply in the world, causing higher costs per medication.
Growth Drivers
Rising gastroenteritis cases
The growing stomach-based health problems are registering new demand for esomeprazole medicine. According to data from city hospitals published by Hindustan Times, in April 2023, there is a 25 to 30% rise in the number of patients taking treatment due to a rise in gastroenteritis cases over the past couple of weeks in India. This is due to the increasing intake of contaminated water and food in the summer. The rising gastroenteritis cases are anticipated to facilitate significant demand for this medicine in the future.
The changing eating patterns and rising obesity
The significant shift in consumer eating habits, mainly towards alcohol and coffee consumption, and smoking are some of the major factors leading to acid reflux cases. The rising obesity cases in the world are expected to fuel the need for esomeprazole in the marketplace. According to a 2022 study, there is a significant correlation between obesity and the symptoms of gastroesophageal reflux disease (GERD). The women with a body mass index 25-29.9, who are considered overweight are more than twice as likely to develop acid reflux compared to those with a normal weight.
Restraining Factors
Rising concerns over esomeprazole side-effects
The increased accessibility to the internet is encouraging patients to research medicines before intake. This provided a platform to learn about the side effects and functioning of medication in the human body. The Indian Pharmacopoeia Commission’s Pharmacovigilance Program of India (PvPI) evaluated the esomeprazole drug and revealed the chance of getting hyperprolactinemia as it can lower the prolactin levels.
According to the 2023 study, the use of proton pump inhibitors, which include esomeprazole, lansoprazole, and omeprazole, for longer periods can increase the risk of dementia among patients. These study outcomes are expected to hinder potential demand for the drug in the future.
Report Segmentation
The market is primarily segmented based on product, application, distribution channel, and region.
|
By Product |
By Application |
By Distribution Channel |
By Region |
|
|
|
|
To Understand the Scope of this Report: Speak to Analyst
By Product Analysis
Capsules segment is expected to register the highest growth in the study period
The capsules segment is anticipated to grow at a higher CAGR during the study period, primarily driven by the availability of esomeprazole capsules in the retail space and the rising number of companies offering esomeprazole capsules, which is attributable to the increasing drug production approvals by the US FDA. Furthermore, the ability to act faster than tablets and other product types is contributing to this segmental growth.
By Application Analysis
Gastroesophageal reflux disease segment witnessed the largest market share in 2023
The GERD segment registered the largest market share in 2023 and is likely to retain its market position throughout the forecast period. The rising incidence of GERD in more countries is boosting the expansion of the esomeprazole market. According to a study, it is one of the most highly diagnosed digestive disorders, with a prevalence rate of 20% in the United States. This trend is a major factor contributing to the larger market share of GERD in the esomeprazole market.
The peptic ulcers segment is expected to grow at the fastest rate over the next few years on account of the significant rise in peptic ulcers. The prevalence of peptic ulcer diseases was 10% in 1990, with 500,000 new cases annually in the United States. This in a way facilitates sustainable demand for esomeprazole globally.
By Distribution Channel Analysis
Hospitals & Clinical Pharmacies segment registered a significant market revenue share in 2023
The hospitals and clinical pharmacies segment held a significant market share in revenue in 2023, which is highly accelerated due to the rising number of people having peptic ulcers, GERD, and other disease cases in healthcare settings. The increased accessibility of hospitals in the countries, from rural areas to urban areas, is witnessing significant rise in the doctor consultation, driven by growing government initiatives to promote healthcare infrastructure. This is expected to fuel demand for certain medications, including esomeprazole in the long run.
Regional Insights
North America region registered the largest share of the global market in 2023
The North America region dominated the global market. This growth is due to rising prevalence of GERD and peptic ulcers in the region. According to the Centre for Disease Control, around 25 million people in the United States are expected to have peptic ulcer at least one time in their lifetime.
The Asia Pacific region is projected to be the fastest-growing region with a healthy CAGR during the study period, owing to the growing elderly population and rising gastroesophageal reflux cases. The growing companies engaging in the production of this drug in the region is expected to positively impact market growth
Key Market Players & Competitive Insights
Strategic acquisitions to drive the competition
The esomeprazole market is moderately fragmented and is expected to witness competition due to the presence of several market players. The key market players are showing enormous interest in strategic collaborations, partnerships, and acquisitions in the market. For instance, in December 2022, LG Chem acquired the patent rights for Vimovo, which was developed by AstraZeneca by utilizing naproxen and esomeprazole as ingredients.
Some of the major players operating in the global market include:
- Actavis (US)
- AstraZeneca AB (UK)
- Blaskov (Columbia)
- CQ Lummy (China)
- KernPharm (Spain)
- Mepha (India)
- Mylan (US)
- Sandoz (Switzerland)
- Sanofi (France)
- Saval Pharmaceutical (Chile)
- Stada Arzneimittel AG (Germany)
- Teva Pharmaceuticals (Israel)
Recent Developments in the Industry
- In October 2023, Zydus Lifesciences Limited announced the final approval of esomeprazole magnesium for delayed-release oral suspension, 20mg and 40 mg, from the US FDA.
- In December 2022, Sun Pharma received approval from the Central Drug Standard Organization to produce Esomeprazole dual-release gastro resistant tablets.
Report Coverage
The esomeprazole market report emphasizes on key regions across the globe to provide better understanding of the product to the users. Also, the report provides market insights into recent developments, trends and analyzes the technologies that are gaining traction around the globe. Furthermore, the report covers in-depth qualitative analysis pertaining to various paradigm shifts associated with the transformation of these solutions.
The report provides detailed analysis of the market while focusing on various key aspects such as competitive analysis, product, application, distribution channel, and their futuristic growth opportunities.
Esomeprazole Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2024 |
USD 1,904.40 million |
|
Revenue forecast in 2032 |
USD 2,872.07 million |
|
CAGR |
5.3% from 2024 – 2032 |
|
Base year |
2023 |
|
Historical data |
2019 – 2022 |
|
Forecast period |
2024 – 2032 |
|
Quantitative units |
Revenue in USD million and CAGR from 2024 to 2032 |
|
Segments covered |
|
|
Regional scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, region and segmentation. |
FAQ's
The Esomeprazole Market report covering key segments are product, application, distribution channel and region.
Esomeprazole Market Size Worth $2,872.07 Million By 2032
Esomeprazole Market exhibiting the CAGR of 5.3% during the forecast period.
North America is leading the global market
key driving factors in Esomeprazole Market are Rising gastroenteritis cases drives the market
© 2024 Polaris Market Research and Consulting. All rights reserved
